Prognosis
Novavax Covid Vaccine Wins European Approval After Months of Delays
- Vaccine would be first protein-based Covid shot in Europe
- European authorization for Novavax is expected imminently
This article is for subscribers only.
Novavax Inc.’s vaccine was cleared by European regulators and is set to become the first Covid-19 shot of its kind in the region, giving countries another tool as they race to protect their populations in the face of the omicron variant.
The protein-based shot, known as Nuvaxovid, was recommended by the European Medicines Agency, according to a statement Monday, and a European Commission decision authorizing the vaccine is expected imminently.